Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Evrysdi, also known by its generic name Risdiplam, is a medication prescribed to treat spinal muscular atrophy (SMA). It is the first oral medication that the Food and Drug Administration has approved for this purpose. Risdiplam works by modifying the splicing of survival of motor neuron 2 (SMN2) genes, thus increasing the production of the SMN protein, which is key for the maintenance of motor neurons. It's appropriate for use in adults, children, and infants who have been diagnosed with SMA.
Evrysdi is administered by mouth once daily following a meal. It should be taken roughly at the same time each day to maintain a consistent level of medication in the body. For infants, it is important to administer Evrysdi after breastfeeding and the drug must not be mixed with formula or milk. Daily dosages of Evrysdi are based on weight, with a maximum recommended daily dose of 5 mg.
If the patient uses a G-tube or NG-tube, they should introduce the medication directly into the tube, followed by a water flush to ensure the full dosage has been delivered. It is critical that once Evrysdi is prepared in the oral syringe, the patient should take it immediately; any medication not consumed within 5 minutes should be discarded, and a new dose prepared. When taking Evrysdi, patients should also drink water to ensure the drug has been completely swallowed.
Evrysdi contains the active ingredient Risdiplam.
No contraindications are listed on the Evrysdi medication label. However, people with a history of hypersensitivity reactions to Risdiplam or any ingredients of the formulation should avoid taking it.
Common side effects of Evrysdi include fever, diarrhea, and various types of skin rashes. Patients may also encounter upper respiratory tract infections, cough, and digestive issues like constipation and vomiting. These symptoms are reported across different individuals and can vary in severity.
While most side effects are manageable, Evrysdi can also cause more severe reactions. These include mouth ulcers, joint pain, and urinary tract infections, which may require medical attention. Given its broad use across various patient ages, including infants and young children, monitoring for these reactions is key. Caregivers and patients should report any severe or worsening symptoms to their healthcare provider promptly to manage and adjust treatment as necessary.